BioGeneration Ventures

Daniela Couto is a General Partner at BioGeneration Ventures. She holds a PhD in Biomedical Engineering and brings over 10 years of experience in venture capital and early-stage biotechnology company development, including work on Staten Biotech, which achieved a $485 million transaction at the pre-clinical stage.

Yash Hemaraj is a Partner at BGV who has led or co-led investments and co-founded Arka Venture Labs, an accelerator helping India-based B2B companies scale globally. His investment focus includes intelligent automation, robotics, and customer-centric applications built on AI/ML, IoT, and computer vision. Before BGV he was one of the first engineers at SpiderCloud Wireless (acquired by Corning), where he worked on indoor wireless systems and holds 4 patents; he earned an MBA from Kellogg, an MS in Electrical Engineering from the University of Maryland, and a BE from NIT Karnataka.

Max Klement is a Partner in Venture Investments at Novo Holdings. He has an engineering background and experience in the global biotech industry, focusing on the development and translation of biomedical science toward human health applications.

Rianne Ellenbroek is a Principal at BioGeneration Ventures with 15 years of experience in life sciences venture capital, spanning company creation, seed and Series A funding, and fund management. She has worked across technology transfer, biotech, and academic sectors.

Wouter Verhoeven is Chief Executive Officer at Brandaris Therapeutics and Venture Partner at BioGeneration Ventures. He brings over 20 years of biotechnology experience, including 15 years in business development and private equity investment, with particular expertise in M&A and in- and out-licensing transactions across North American, European, and Asian markets. He has held executive leadership positions at two biotech companies, where he managed global business development and corporate development functions.

Alexander Vos is Chairman of the Board at Scenic Biotech and Managing Director of Biotech Mountains. He has held executive and board positions in biopharmaceuticals, with experience in orphan and rare diseases, cell and gene therapy, strategy, investor relations, and mergers and acquisitions. He holds an MBA from Stanford University Graduate School of Business.

Robbert leads fundraising and investor relations at BGV and heads Forbion's ESG and impact investing efforts. He previously founded Accretion Capital Partners and was a partner at Virage Capital and Neotech Capital, with over 20 years of experience across Asia, Europe, and North America, and holds a Business Economics degree from Erasmus University Rotterdam.